Dis-Chem Pharmacies Limited - Laporan Laba Rugi (TTM)

Dis-Chem Pharmacies Limited
ZA ˙ JSE ˙ ZAE000227831
ZAR 3,234.00 ↓ -4.00 (-0.12%)
2025-09-05
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Dis-Chem Pharmacies Limited menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
11-30
2021
02-28
2021
05-31
2021
08-31
2021
11-30
2022
02-28
2022
05-31
2022
08-31
2022
11-30
2023
02-28
2023
05-31
2023
08-31
2023
11-30
2024
02-29
2024
05-31
2024
08-31
2024
11-30
2025
02-28
Revenue 25,611 26,278 27,343 28,407 29,407 30,407 31,102 31,798 32,231 32,664 33,427 34,191 35,237 36,283 37,137 37,990 38,581 39,172
Change (%) 2.60 4.05 3.89 3.52 3.40 2.29 2.24 1.36 1.34 2.34 2.29 3.06 2.97 2.35 2.30 1.56 1.53
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 19,831 20,442 21,299 22,156 22,866 23,576 23,986 24,396 24,736 25,076 25,766 26,456 27,262 28,067 28,724 29,381 29,876 30,372
Change (%) 3.08 4.19 4.02 3.21 3.11 1.74 1.71 1.39 1.38 2.75 2.68 3.04 2.95 2.34 2.29 1.69 1.66
% of Revenue 77.43 77.79 77.90 77.99 77.76 77.54 77.12 76.72 76.75 76.77 77.08 77.38 77.37 77.35 77.35 77.34 77.44 77.53
Gross Operating Profit 5,780 5,836 6,044 6,252 6,541 6,830 7,116 7,403 7,495 7,587 7,661 7,735 7,976 8,217 8,413 8,610 8,705 8,800
Change (%) 0.98 3.56 3.43 4.63 4.42 4.19 4.02 1.25 1.23 0.97 0.96 3.11 3.02 2.39 2.34 1.11 1.10
% of Revenue 22.57 22.21 22.10 22.01 22.24 22.46 22.88 23.28 23.25 23.23 22.92 22.62 22.63 22.65 22.65 22.66 22.56 22.47
SG&A 4,506 4,964 4,964 4,964 2,894 824 824 824 915 1,006 1,006 1,006 1,121 1,236 1,236 1,236 1,287 1,337
Change (%) 10.15 0.00 0.00 -41.70 -71.52 0.00 0.00 11.03 9.94 0.00 0.00 11.45 10.27 0.00 0.00 4.07 3.91
% of Revenue 17.59 18.89 18.15 17.47 9.84 2.71 2.65 2.59 2.84 3.08 3.01 2.94 3.18 3.41 3.33 3.25 3.33 3.41
R&D
Change (%)
% of Revenue
OpEx 24,281 24,937 25,926 26,915 27,891 28,867 29,476 30,085 30,502 30,919 31,711 32,502 33,503 34,504 35,281 36,057 36,563 37,068
Change (%) 2.70 3.97 3.81 3.63 3.50 2.11 2.07 1.39 1.37 2.56 2.50 3.08 2.99 2.25 2.20 1.40 1.38
% of Revenue 94.81 94.90 94.82 94.75 94.84 94.94 94.77 94.61 94.64 94.66 94.86 95.06 95.08 95.10 95.00 94.91 94.77 94.63
Operating Income 1,330 1,341 1,417 1,492 1,516 1,539 1,627 1,714 1,729 1,744 1,717 1,690 1,734 1,779 1,856 1,933 2,018 2,104
Change (%) 0.85 5.64 5.33 1.57 1.55 5.66 5.36 0.89 0.88 -1.56 -1.59 2.65 2.58 4.32 4.14 4.43 4.24
% of Revenue 5.19 5.10 5.18 5.25 5.16 5.06 5.23 5.39 5.36 5.34 5.14 4.94 4.92 4.90 5.00 5.09 5.23 5.37
Interest Expense -356 -345 -341 -338 -331 -325 -320 -315 -343 -370 -397 -424 -445 -466 -490 -513 -517 -521
Change (%) -3.31 -1.00 -1.01 -1.90 -1.94 -1.50 -1.53 8.79 8.08 7.22 6.73 4.99 4.76 5.01 4.77 0.79 0.78
% of Revenue -1.39 -1.31 -1.25 -1.19 -1.13 -1.07 -1.03 -0.99 -1.06 -1.13 -1.19 -1.24 -1.26 -1.28 -1.32 -1.35 -1.34 -1.33
Net Income 655 669 722 776 815 853 946 1,040 1,020 1,000 949 899 942 984 1,023 1,061 1,121 1,180
Change (%) 2.10 8.01 7.41 5.01 4.77 10.90 9.83 -1.89 -1.93 -5.08 -5.35 4.78 4.56 3.90 3.75 5.59 5.29
% of Revenue 2.56 2.54 2.64 2.73 2.77 2.81 3.04 3.27 3.16 3.06 2.84 2.63 2.67 2.71 2.75 2.79 2.90 3.01

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista